Ozempic, a medication initially developed for type 2 diabetes, has gained popularity as a weight loss aid. However, recent expert insights suggest that its use may lead to unintended muscle loss, raising concerns about long-term health implications.
Dr. Ben Bickman, a scientist at Brigham Young University, highlights that weight loss from Ozempic isn’t solely fat reduction. He notes that for every ten pounds lost, approximately four pounds may come from muscle and bone mass. This loss is particularly troubling as muscle and bone are harder to regain compared to fat.
Dr. Bickman also points out that some versions of these drugs might stimulate the production of new fat cells. Consequently, after discontinuing Ozempic, individuals might regain fat more rapidly, potentially leading to a higher body fat percentage than before starting the medication.
Clinical studies have observed that participants using GLP-1 receptor agonists like semaglutide (Ozempic) experienced significant muscle mass reduction. In some trials lasting up to 72 weeks, users lost 10% or more of their muscle mass, underscoring the need for caution and further research into these effects.
While Ozempic is effective at reducing cravings initially, Dr. Bickman notes that this effect may wane after approximately two years of use. As cravings return, individuals might find it challenging to maintain weight loss, especially if muscle mass has been compromised.
